title: Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.
abstract: Neutrophilic panniculitis is a rare adverse effect of therapy with selective BRAF inhibitors. We report a case of neutrophilic panniculitis in a 15-year-old girl receiving treatment with vemurafenib for a brainstem glioma. Clinicians should be aware of this rare but important side effect of vemurafenib. This is the first report of neutrophilic panniculitis in a child treated with vemurafenib.
authors.affiliation: Columbia University College of Physicians and Surgeons, New York, New York.
authors.forename: Emily S
authors.initials: ES
authors.lastname: West
authors.forename: Victoria L
authors.initials: VL
authors.lastname: Williams
authors.forename: Joseph G
authors.initials: JG
authors.lastname: Morelli
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D020295:Brain Stem Neoplasms / Q000188:drug therapy; D005260:Female; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D009504:Neutrophils / Q000473:pathology*; D015434:Panniculitis / Q000139:chemically induced* / Q000473:pathology; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf